# Possible Differences in HCC Course Depending on DAA Treatment

> **NCT05376943** · — · UNKNOWN · sponsor: **Medical University of Warsaw** · enrollment: 100 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular
- Hepatitis C Virus Infection, Response to Therapy of
- Drug Effect
- Drug Side Effect
- Hepatitis C, Chronic
- Liver Cirrhosis

## Interventions

- **DRUG:** Direct Acting Antivirals

## Key facts

- **NCT ID:** NCT05376943
- **Lead sponsor:** Medical University of Warsaw
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-10
- **Primary completion:** 2022-10
- **Final completion:** 2022-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05376943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05376943, "Possible Differences in HCC Course Depending on DAA Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05376943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*